Item 7.01 Regulation FD Disclosure.

On February 17, 2023, CinCor Pharma, Inc. (the "Company") received the official meeting minutes from the End-of-Phase 2 meeting that the Company held with the U.S. Food and Drug Administration on January 18, 2023 with respect to the anticipated Phase 3 program for baxdrostat in hypertension. A press release announcing receipt of the meeting minutes is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.        Description

99.1           Press Release issued by CinCor Pharma, Inc., dated February 21, 2023

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses